Cell & Gene Therapies: A Regulatory Update

Return to Insights Center

Related Insights

Playbook

Mitigating risk, protecting potential: Practical strategies that position cell and gene therapy development for success

Mar 28, 2023

Report

New Medicines, Novel Insights: Accelerating development of cell and gene therapies

May 22, 2023

Article

Three ways to improve your chances that insurers will pay for a new CGT

Feb 18, 2021

Podcast

Rare endpoints: Delivering on unmet patient needs

May 7, 2024

Blog

CAR-T boxed warnings: regulatory precedents and opportunities

Feb 9, 2024

Blog

CAR-T product development: an assessment of FDA’s final guidance for industry

Feb 27, 2024

Podcast

CAR-T boxed warnings: What comes next?

Mar 6, 2024

Blog

Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial

Nov 19, 2021

Blog

Making cell and gene therapy more accessible in the treatment of solid tumors

Jun 4, 2024

Blog

Population variability: important considerations in vaccine development

Jun 14, 2023

Blog

Celebrating 40 Years of Rare Disease Progress: WODC Highlights

Jun 6, 2023

Blog

FDA’s new priority voucher review program: Potential implications and next steps for sponsors

Jun 20, 2025

Related Insights

Playbook

Mitigating risk, protecting potential: Practical strategies that position cell and gene therapy development for success

Mar 28, 2023

Report

New Medicines, Novel Insights: Accelerating development of cell and gene therapies

May 22, 2023

Article

Three ways to improve your chances that insurers will pay for a new CGT

Feb 18, 2021

Podcast

Rare endpoints: Delivering on unmet patient needs

May 7, 2024

Blog

CAR-T boxed warnings: regulatory precedents and opportunities

Feb 9, 2024

Blog

CAR-T product development: an assessment of FDA’s final guidance for industry

Feb 27, 2024

Show more